Edition:
India

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

119.79USD
25 Sep 2018
Change (% chg)

$2.14 (+1.82%)
Prev Close
$117.65
Open
$117.65
Day's High
$120.40
Day's Low
$117.38
Volume
32,691
Avg. Vol
204,880
52-wk High
$124.38
52-wk Low
$51.11

Chart for

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -2.06
Market Cap(Mil.): $1,754.86
Shares Outstanding(Mil.): 25.10
Dividend: --
Yield (%): --

Financials

BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln

* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE

08 May 2018

BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million

* INTERCEPT PHARMACEUTICALS SAYS CEO MARK PRUZANSKI'S FY 2017 TOTAL COMPENSATION WAS $6.2 MILLION VERSUS $4.8 MILLION IN 2016 - SEC FILING Source text for Eikon: (http://bit.ly/2KlDqOX) Further company coverage:

28 Apr 2018

BRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors

* INTERCEPT PHARMACEUTICALS SAYS EFFECTIVE APRIL 24, CO'S BOARD INCREASED SIZE OF BOARD FROM NINE DIRECTORS TO TEN DIRECTORS - SEC FILING Source text: [https://bit.ly/2JsU4uo] Further company coverage:

27 Apr 2018

BRIEF-Intercept Pharmaceuticals Announces Pricing Of Upsized $250 Mln Public Offering And Concurrent Private Placement Of Common Stock

* INTERCEPT PHARMACEUTICALS ANNOUNCES PRICING OF UPSIZED $250 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT OF COMMON STOCK

05 Apr 2018

BRIEF-Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31

* EXPECTS NET SALES OF OCALIVA FOR QUARTER ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QUARTER ENDED DEC 31, 2017​ Source text (https://bit.ly/2uINGwG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

05 Apr 2018

BRIEF-Intercept Pharma Says U.S. Court Granted Defendants Motion & Dismissed With Prejudice Derivative Lawsuit Purportedly Brought On Behalf Of Company

* INTERCEPT PHARMA - U.S. COURT GRANTED DEFENDANTS MOTION & DISMISSED WITH PREJUDICE DERIVATIVE LAWSUIT PURPORTEDLY BROUGHT ON BEHALF OF COMPANY

27 Mar 2018

Competitors

Earnings vs. Estimates